Trial Profile
A Prospective study of Conversion Therapy Using Docetaxel Chemotherapy Plus Apatinib in Unresectable Adenocarcinoma of Esophagogastric Junction AEG
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 07 Sep 2017 New trial record